Provided by Tiger Trade Technology Pte. Ltd.

uniQure NV

23.86
-0.1750-0.73%
Volume:876.43K
Turnover:20.83M
Market Cap:1.49B
PE:-5.49
High:24.28
Open:23.43
Low:23.03
Close:24.03
52wk High:71.50
52wk Low:7.76
Shares:62.29M
Float Shares:40.64M
Volume Ratio:1.04
T/O Rate:2.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3443
EPS(LYR):-4.9242
ROE:-165.27%
ROA:-13.89%
PB:6.50
PE(LYR):-4.84

Loading ...

Rosen Law Firm urges uniQure investors to act before April 13 lead plaintiff deadline

Reuters
·
Yesterday

uniQure Initiated at Peer Perform by Wolfe Research

Dow Jones
·
Feb 24

uniQure initiated with a Peer Perform at Wolfe Research

TIPRANKS
·
Feb 24

uniQure NV updated its financial calendar

Reuters
·
Feb 23

uniQure to Announce 2025 Financial Results

GlobeNewswire
·
Feb 23

Class Action Lawsuit Targets uniQure NV Over Alleged Securities Fraud

Reuters
·
Feb 18

Investors Sue uniQure NV Over Alleged Misleading Disclosures

Reuters
·
Feb 17

uniQure Faces Class Action Over Alleged Misleading Statements on Drug Approval

Reuters
·
Feb 14

Assessing uniQure (QURE) Valuation After New Securities Fraud Lawsuit On AMT-130 Disclosures

Simply Wall St.
·
Feb 12

uniQure Price Target Maintained With a $70.00/Share by HC Wainwright & Co.

Dow Jones
·
Feb 10

How Early AMT-191 Gene Therapy Signals Will Impact uniQure (QURE) Investors

Simply Wall St.
·
Feb 09

Early uniQure Fabry Trial Shows Lasting Enzyme Boost, Safety Watch

Benzinga_recent_news
·
Feb 07

uniQure präsentiert neue Phase-I/IIa-Daten zur Gentherapie AMT-191 bei Fabry-Krankheit

Reuters
·
Feb 06

uniQure Reports Sustained Enzyme Increases in Phase I/IIa Fabry Disease Gene Therapy Trial

Reuters
·
Feb 06

A Look At uniQure (QURE) Valuation After FDA Setback And Legal Investigations

Simply Wall St.
·
Feb 04

uniQure Initiated at Equal-Weight by Barclays

Dow Jones
·
Jan 28

Barclays Initiates Coverage on uniQure N.V With Equal Weight Rating, $31 Price Target

MT Newswires Live
·
Jan 28

uniQure initiated with an Equal Weight at Barclays

TIPRANKS
·
Jan 28

uniQure NV Director Robert Gut Reports Disposal of Common Shares

Reuters
·
Jan 15

uniQure Showcases Gene Therapy Leadership and Pipeline Progress in New Corporate Presentation

Reuters
·
Jan 13